ATE354592T1 - Vegf-antagonisten zur behandlung von diabetes - Google Patents

Vegf-antagonisten zur behandlung von diabetes

Info

Publication number
ATE354592T1
ATE354592T1 AT04758372T AT04758372T ATE354592T1 AT E354592 T1 ATE354592 T1 AT E354592T1 AT 04758372 T AT04758372 T AT 04758372T AT 04758372 T AT04758372 T AT 04758372T AT E354592 T1 ATE354592 T1 AT E354592T1
Authority
AT
Austria
Prior art keywords
vegf
treating diabetes
vegf antagonists
blocking
mediated activity
Prior art date
Application number
AT04758372T
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE354592T1 publication Critical patent/ATE354592T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04758372T 2003-03-28 2004-03-26 Vegf-antagonisten zur behandlung von diabetes ATE354592T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
ATE354592T1 true ATE354592T1 (de) 2007-03-15

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04758372T ATE354592T1 (de) 2003-03-28 2004-03-26 Vegf-antagonisten zur behandlung von diabetes

Country Status (17)

Country Link
US (1) US7052691B2 (de)
EP (1) EP1608685B1 (de)
JP (2) JP4730909B2 (de)
AT (1) ATE354592T1 (de)
AU (1) AU2004226417B2 (de)
BR (1) BRPI0408749B1 (de)
CA (1) CA2519787C (de)
CY (1) CY1106530T1 (de)
DE (1) DE602004004883T2 (de)
DK (1) DK1608685T3 (de)
ES (1) ES2278333T3 (de)
HK (1) HK1080092A1 (de)
MX (1) MXPA05008972A (de)
PL (1) PL1608685T3 (de)
PT (1) PT1608685E (de)
SI (1) SI1608685T1 (de)
WO (1) WO2004087206A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997386B (zh) * 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
CN101141975B (zh) 2005-03-25 2012-05-23 瑞泽恩制药公司 Vegf拮抗剂制剂
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2648809T3 (es) 2014-01-25 2018-01-08 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína de fusión que inhibe la angiogénesis o el crecimiento y uso de esta
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (de) 2014-07-18 2019-04-10 Sanofi Verfahren zur vorhersage des ausgangs einer behandlung mit aflibercept bei einem patienten mit verdacht auf ein krebsleiden
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
ES2319305T3 (es) * 1999-06-08 2009-05-06 Regeneron Pharmaceuticals, Inc. Quimeras del receptor del vegf para el tratamiento de trastornos oculares caracterizados por la permeabilidad vascular.
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases

Also Published As

Publication number Publication date
DE602004004883D1 (de) 2007-04-05
WO2004087206A2 (en) 2004-10-14
US20040213787A1 (en) 2004-10-28
MXPA05008972A (es) 2005-11-04
EP1608685B1 (de) 2007-02-21
SI1608685T1 (sl) 2007-08-31
PL1608685T3 (pl) 2007-07-31
BRPI0408749A (pt) 2006-03-28
EP1608685A2 (de) 2005-12-28
WO2004087206A3 (en) 2004-12-16
DE602004004883T2 (de) 2007-11-15
BRPI0408749B1 (pt) 2016-10-04
CA2519787A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24
JP2006521397A (ja) 2006-09-21
CY1106530T1 (el) 2012-01-25
JP4730909B2 (ja) 2011-07-20
AU2004226417B2 (en) 2009-01-22
US7052691B2 (en) 2006-05-30
AU2004226417A1 (en) 2004-10-14
CA2519787C (en) 2012-06-05
ES2278333T3 (es) 2007-08-01
HK1080092A1 (en) 2006-04-21
DK1608685T3 (da) 2007-06-11
PT1608685E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
NO20070506L (no) Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer.
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
DE602005009318D1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE506456T1 (de) Verfahren zur behandlung von lentivirusinfektionen
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ATE428712T1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
ATE471326T1 (de) Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
DE60129330D1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
ATE551054T1 (de) Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus
WO2005070042A3 (en) Novel chemical compounds
ATE443044T1 (de) Tace inhibitoren
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60229123D1 (de) Behandlung von fibromyalgie mit pindolol
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60327655D1 (de) Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608685

Country of ref document: EP